Cargando…

Residual Adrenal Function in Autoimmune Addison’s Disease—Effect of Dual Therapy With Rituximab and Depot Tetracosactide

CONTEXT: In autoimmune Addison’s disease (AAD), exogenous glucocorticoid (GC) therapy is an imperfect substitute for physiological GC secretion. Patients on long-term steroid replacement have increased morbidity, reduced life expectancy, and poorer quality of life. OBJECTIVE: The objective of this a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Napier, Catherine, Gan, Earn H, Mitchell, Anna L, Gilligan, Lorna C, Rees, D Aled, Moran, Carla, Chatterjee, Krishna, Vaidya, Bijay, James, R Andrew, Mamoojee, Yaasir, Ashwell, Simon, Arlt, Wiebke, Pearce, Simon H S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Online Only Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067544/ https://www.ncbi.nlm.nih.gov/pubmed/31863094 http://dx.doi.org/10.1210/clinem/dgz287

Ejemplares similares

Natural History of Adrenal Steroidogenesis in Autoimmune Addison’s Disease Following Diagnosis and Treatment
por: Napier, Catherine, et al.
Publicado: (2020)

Spontaneous and tetracosactide‐induced anti‐ACTH antibodies in man
por: Gan, Earn H., et al.
Publicado: (2015)

MANAGEMENT OF ENDOCRINE DISEASE: Residual adrenal function in Addison’s disease
por: Pearce, Simon H S, et al.
Publicado: (2020)

Impact of Month of Birth on the Risk of Development of Autoimmune Addison's Disease
por: Pazderska, Agnieszka, et al.
Publicado: (2016)

Autoimmune Thyroid Disorders in Autoimmune Addison Disease
por: Meling Stokland, Ann-Elin, et al.
Publicado: (2022)

The role of functionally defective rare germline variants of sialic acid acetylesterase in autoimmune Addison's disease
por: Gan, Earn H, et al.
Publicado: (2012)

Heterogeneous natural history of Addison’s disease: mineralocorticoid deficiency may predominate
por: Howarth, Sophie, et al.
Publicado: (2022)

Linkage Analysis in Autoimmune Addison’s Disease: NFATC1 as a Potential Novel Susceptibility Locus
por: Mitchell, Anna L., et al.
Publicado: (2015)

Correction: Linkage Analysis in Autoimmune Addison’s Disease: NFATC1 as a Potential Novel Susceptibility Locus
por: Mitchell, Anna L., et al.
Publicado: (2015)

Rifabutin-Induced SIADH and Leucopenia in a Renal Transplant Recipient with Genitourinary Tract Tuberculosis: A Case Report and Review of the Literature
por: Mohamed, Maha, et al.
Publicado: (2022)

Increased Infection Risk in Addison’s Disease and Congenital Adrenal Hyperplasia: A Primary Care Database Cohort Study
por: Tresoldi, Alberto S, et al.
Publicado: (2019)

Safety and tolerability of one-year intramuscular testosterone regime to induce puberty in older men with CHH
por: Pazderska, Agnieszka, et al.
Publicado: (2017)

Effect of Tetracosactid on Post Partum Cyclicity in Cows after Induction of Parturition with PGF(2α)
por: Veronesi, MC, et al.
Publicado: (2001)

Women With Polycystic Ovary Syndrome Have an Increased Risk of Major Cardiovascular Events: a Population Study
por: Berni, Thomas R, et al.
Publicado: (2021)

Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma
por: Chortis, Vasileios, et al.
Publicado: (2019)

A Variant in the BACH2 Gene Is Associated With Susceptibility to Autoimmune Addison's Disease in Humans
por: Pazderska, Agnieszka, et al.
Publicado: (2016)

PB2071: INTRALESIONAL RITUXIMAB IN THE TREATMENT OF PRIMARY CUTANEOUS B-CELL LYMPHOMA
por: Callejas Charavia, M., et al.
Publicado: (2022)

Comparative effects of methylprednisolone and tetracosactide (ACTH(1–24)) on ischemia/reperfusion injury of the rabbit spinal cord
por: Kertmen, Hayri, et al.
Publicado: (2017)

PB2701: SAFETY OF 30 MINUTES INFUSION OF RITUXIMAB BIOSIMILAR. A COHORT STUDY.
por: Palomares, Laida Cuevas, et al.
Publicado: (2023)

PB2312: REACTIVATION OF HEPATITIS B VIRUS FOLLOWING RITUXIMAB IN B LYMPHOID HEMOPATHIES
por: Wafa, Miled, et al.
Publicado: (2023)

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
por: Sharman, J. P., et al.
Publicado: (2022)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

Loperamide-induced hypopituitarism
por: Napier, Catherine, et al.
Publicado: (2016)

PB2267: COVID-19 OUTCOMES ON HAEMATOLOGY PATIENTS WHO RECEIVED RITUXIMAB: SINGLE CENTRE STUDY
por: Hariharan, L., et al.
Publicado: (2022)

ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency
por: Arlt, Wiebke, et al.
Publicado: (2020)

PB2070: EFFICACY OF RITUXIMAB MAINTENANCE THERAPY IN ADVANCED-STAGE FOLLICULAR LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE STUDY.
por: Amorós, C., et al.
Publicado: (2022)

Does Obesity Cause Thyroid Cancer? A Mendelian Randomization Study
por: Fussey, Jonathan Mark, et al.
Publicado: (2020)

It is Time to Carpe Diem with Porcine ACTH – A Comparison of Porcine Sequence Corticotropin to Tetracosactide Hexaacetate in Testing the Hypothalamic Pituitary Adrenal Axis in Healthy Individuals
por: Wagmode, Nalini B., et al.
Publicado: (2018)

Acute Hypercortisolemia Exerts Depot-Specific Effects on Abdominal and Femoral Adipose Tissue Function
por: Manolopoulos, Konstantinos N., et al.
Publicado: (2017)

PB2097: ZANUBRUTINIB PLUS RITUXIMAB FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE-B CELL LYMPHOMA
por: Bai, J.-F., et al.
Publicado: (2022)

PB2315: EFFICACY AND SAFETY OF TWO DIFFERENT LOW-DOSE RITUXIMAB REGIMENS FOR CHINESE CHILDREN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA
por: Zhu, X.
Publicado: (2022)

PB2315: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZR OR ZRM REGIMEN (ZANUBRUTINIB, RITUXIMAB, METHOTREXATE)
por: Teng, Yue, et al.
Publicado: (2023)

PB2105: REAL WORLD EXPERIENCE WITH POLATUZUMAB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR R/R DLBCL IN 3 ACADEMIC CENTERS IN MADRID, SPAIN.
por: Corrochano, M., et al.
Publicado: (2022)

PB2084: FIRST-LINE TREATMENT IN ADVANCED STAGE FOLICULAR LYMPHOMA: A SINGLE-CENTER EXPERIENCE WITH R-CHOP VS BENDAMUSTINE-RITUXIMAB.
por: Mompel, O., et al.
Publicado: (2022)

Addison's disease
por: Sarkar, Soumya Brata, et al.
Publicado: (2012)

Addison's Disease
Publicado: (1890)

Addison's Anæmia
Publicado: (1902)

Dr Addison
Publicado: (1860)

Addison’s Disease
por: Rochester, Thos. F.
Publicado: (1880)

Addison’s Disease
por: Rochester, Thos. F.
Publicado: (1880)

Cannot write session to /tmp/vufind_sessions/sess_91ncotci3otn9r6hrari6o4rt0